Michael Maris

[Michael Maris @MichaelMaris8]

After Elon Musks disgusting lying tweet I am happily saying goodbye to twitter. Be safe friends and vote.

[Michael Maris @MichaelMaris8]

So this is where we are as a country where the republican party can incite violence on the family of their political opponents and then use their propaganda arm to blame the victim? Welcome to fascism 101.

[Michael Maris @MichaelMaris8]

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial | Critical Care Medicine | JAMA Internal Medicine | JAMA Network https://t.co/WGkU2voIL2

[Michael Maris @MichaelMaris8]

via ⁦@nytimes⁩ https://t.co/o6CL947bLq

[Michael Maris @MichaelMaris8]

BNT162b2 COVID‐19 vaccine is significantly less effective in patients with disease hematologic malignancies - Herzog Tzarfati - - American Journal of Hematology - Wiley Online Library

Even more reason to encourage all Americans vaccinated! https://t.co/oOi4vdvzVj

[Michael Maris @MichaelMaris8]

Join the #CBCI virtual #CBCIASHREVIEW taking place this Thursday the 4th at 6pm!!!Amazing speakers. https://t.co/JFHkXyPKfb

[Michael Maris @MichaelMaris8]

https://t.co/d4pbfBtrzq
#ASH20 #CBCI
Venetoclax combinations with DMA and next generation FLT3 inhibitors appear exceptionally promising in multiple settings. Allogeneic transplant for consolidation after this therapy appears to enhance these outcomes!

[Michael Maris @MichaelMaris8]

Just about to spend some time being educated by my old friend and former roommate at the FHCRC Professor Uwe Platzbecker! Go Uwe! #CBCI

[Michael Maris @MichaelMaris8]

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors | Blood | American Society of Hematology https://t.co/uO5Iad4JPo

[Michael Maris @MichaelMaris8]

My vote counts! #IVoted in the 2020 Presidential Election! #DenverVotes https://t.co/yj5g97lRHs via @DenverElections

[Michael Maris @MichaelMaris8]

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
Rituximab improves nonmyeloablative allogeneic HSCT transplant for CLL. #CBCI https://t.co/7ypbiVwU0c

[Michael Maris @MichaelMaris8]

Triple therapy makes HLA class 1&2 antigen mismatched mini-allo safe and effective. This a study from the Hutch consortium that included good ol’ #CBCI !!!!

[Michael Maris @MichaelMaris8]

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors | Blood | American Society of Hematology https://t.co/lJOLoZqBf8

[Michael Maris @MichaelMaris8]

@AdamParkhomenko Thank you.

[Michael Maris @MichaelMaris8]

Important study. The mini outcomes continue to get better!

Allogeneic Hematopoietic Cell Transplantation With Non-Myeloablative Conditioning For Patients With Hematologic Malignancies: Improved Outcomes Over Two Decades
Haematologica June 2020 : haematol.2020.248187; Doi:10

[Michael Maris @MichaelMaris8]

ARTICLES| VOLUME 6, ISSUE 8, E409-E418, AUGUST 01, 2019
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative... advancing GVHD ppx #CBCI

[Michael Maris @MichaelMaris8]

Where is the CDC in the COVID 19 pandemic?? Why aren’t these scientists directing our response? This is not political. Let the CDC do its job!! #FreetheCDC!

[Michael Maris @MichaelMaris8]

⁦@ColoradoBlood⁩ CBCI ASH review. somebody build me a snowman!

[Michael Maris @MichaelMaris8]

Dr Conner rocking aggressive lymphoma ⁦@ColoradoBlood⁩ ASH2019 review!!